Diagonal Bio AB (publ) (NGM:DIABIO)

Diagonal Bio AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1.35	1.13	3.15	3.71	8.67	8
Revenue Growth (YoY)	-43.06%	-64.30%	-14.98%	-57.26%	8.41%	-
Cost of Revenue	0.33	0.18	0.02	1.65	8.76	8.07
Gross Profit	1.02	0.94	3.13	2.05	-0.09	-0.07
Selling, General & Admin	8.95	9.36	14.68	17.22	11.55	0.74
Other Operating Expenses	-0	-0	0.02	-0	0.03	-0.03
Operating Expenses	10.25	10.36	14.7	17.22	11.58	0.71
Operating Income	-9.22	-9.42	-11.57	-15.16	-11.66	-0.78
Interest Expense	-0.32	-0.58	-0.21	-1	-	-
Interest & Investment Income	0.08	0.08	0.09	-	-	-
Other Non Operating Income (Expenses)	-	-	0	-	-	-
Pretax Income	-9.47	-9.93	-11.68	-16.16	-11.66	-0.78
Net Income	-9.47	-9.93	-11.68	-16.16	-11.66	-0.78
Net Income to Common	-9.47	-9.93	-11.68	-16.16	-11.66	-0.78
Shares Outstanding (Basic)	-	280	36	9	7	4
Shares Outstanding (Diluted)	-	280	36	9	7	4
Shares Change (YoY)	-	668.77%	284.00%	38.15%	96.47%	-
EPS (Basic)	-	-0.04	-0.32	-1.70	-1.70	-0.22
EPS (Diluted)	-	-0.04	-0.32	-1.70	-1.70	-0.22
Gross Margin	75.68%	83.73%	99.43%	55.42%	-0.98%	-0.87%
Operating Margin	-681.67%	-837.42%	-367.09%	-409.15%	-134.52%	-9.72%
Profit Margin	-699.93%	-882.67%	-370.61%	-436.16%	-134.52%	-9.72%
EBITDA	-7.92	-8.41	-11.56	-	-	-
D&A For EBITDA	1.31	1.01	0	-	-	-
EBIT	-9.22	-9.42	-11.57	-15.16	-11.66	-0.78
EBIT Margin	-	-	-	-	-134.52%	-9.72%
Revenue as Reported	1.36	1.13	3.18	3.73	8.72	8.12

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.